Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/genetics/gene/fech/

FECH gene

ferrochelatase

Normal Function

The FECH gene provides instructions for making an enzyme known as ferrochelatase. This enzyme is involved in the production of a molecule called heme. Heme is vital for all of the body's organs, although it is most abundant in the blood, bone marrow, and liver. Heme is an essential component of iron-containing proteins called hemoproteins, including hemoglobin (the protein that carries oxygen in the blood).

The production of heme is a multi-step process that requires eight different enzymes. Ferrochelatase is responsible for the eighth and final step in this process, in which an iron atom is inserted into the center of protoporphyrin IX (the product of the seventh step) to form heme.

Health Conditions Related to Genetic Changes

Porphyria

More than 110 mutations in the FECH gene have been identified in individuals with a form of porphyria called erythropoietic protoporphyria. A mutation in one copy of the FECH gene reduces each cell's production of ferrochelatase by about half. However, this is not enough to cause the signs and symptoms of porphyria; people with this disorder must also inherit a second altered copy of FECH. In some affected individuals, the second copy of the FECH gene is also nonfunctional, and cells make almost no ferrochelatase. In other affected individuals, the second copy of the FECH gene retains some of its function. This version of the gene is described as a low-expression allele. It reduces, but does not eliminate, the amount of ferrochelatase produced within cells. A combination of two mutated copies of the FECH gene in each cell, or one mutated copy of the gene and one low-expression allele, is necessary for erythropoietic protoporphyria to develop.

A shortage of functional ferrochelatase allows compounds called porphyrins to build up in developing red blood cells. These compounds are formed during the normal process of heme production, but reduced activity of ferrochelatase allows them to accumulate to toxic levels. The excess porphyrins can leak out of developing red blood cells and be transported through the bloodstream to the skin and other tissues. High levels of these compounds in the skin cause the oversensitivity to sunlight that is characteristic of this condition. Large amounts of porphyrins in the gallbladder can also cause gallstones. Less commonly, a buildup of these compounds in the liver can result in liver damage.

More About This Health Condition

Other Names for This Gene

  • Protoporphyria
  • Protoporphyrin ferrochelatase

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

Scientific Articles on PubMed

Catalog of Genes and Diseases from OMIM

Gene and Variant Databases

References

  • Balwani M, Bloomer J, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Erythropoietic Protoporphyria, Autosomal Recessive. 2012 Sep 27 [updated 2017 Sep 7]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK100826/ Citation on PubMed
  • Bloomer JR, Wang Y, Singhal A, Risheg H. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences. J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S36-40. doi: 10.1097/01.mpg.0000226388.56612.fa. Citation on PubMed
  • Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, Puy H, Deybach JC. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet. 2006 Jan;78(1):2-14. doi: 10.1086/498620. Epub 2005 Nov 15. Citation on PubMed or Free article on PubMed Central
  • Herrero C, To-Figueras J, Badenas C, Mendez M, Serrano P, Enriquez-Salamanca R, Lecha M. Clinical, biochemical, and genetic study of 11 patients with erythropoietic protoporphyria including one with homozygous disease. Arch Dermatol. 2007 Sep;143(9):1125-9. doi: 10.1001/archderm.143.9.1125. Citation on PubMed
  • Risheg H, Chen FP, Bloomer JR. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab. 2003 Sep-Oct;80(1-2):196-206. doi: 10.1016/j.ymgme.2003.07.001. Citation on PubMed

The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.